Allianz’s Ionis Pharmaceuticals IONS Stock Holding History

Allianz’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,100	Closed	-$83K	–	391
2025 Q2	$83K	Buy	+2,100	New	+$68.7K	﹤0.01%	331

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allianz's IONS Position: Q3 2025 in Review

Allianz sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 2,100 shares — an estimated $83K sold.

Allianz first reported a position in IONS in Q2 2025 and held it in 1 quarter. The position peaked at $83K in Q2 2025. 435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

Allianz reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Allianz sold 2,100 Ionis Pharmaceuticals shares in Q3 2025, an estimated $83K.
Allianz first reported a position in Ionis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Allianz's Ionis Pharmaceuticals position peaked at $83K in Q2 2025.
435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on Allianz's 13F filing for Q3 2025, filed 12 Nov 2025.